Home  >  TopNews
you can get e-magazine links on WhatsApp.Click here
Corporate + Font Resize -

Gland Pharma to invest in manufacturing and technological capabilities

Yash Ved, Mumbai
Wednesday, November 25, 2020, 08:00 Hrs  [IST]

Gland Pharma, one of the fastest growing generic injectables-focused company, stated that it will continue to invest in manufacturing and technological capabilities and will be expanding product portfolio and delivery systems.

The company stated that it will be pursuing growth opportunities in China, India, Brazil and will also be focusing on cost management and increasing market share.

The company further stated that it has filed 6 products in FY20 in China and plan to further accelerate filings rate.

The company's mission is to be a global injectables player, providing value-added total solutions.

"We have pipeline of 267 ANDA filing in US. Out of this, 215 are approved and 52 ANDA filings pending for approval. We have multiple growth drivers with robust product pipeline and expansion plans supported by strong track record of new product launches," stated Srinivas Sadu, MD and CEO, Gland Pharma.

Sadu added, “We also have track record of growth and profitability from a diversified revenue base and diversified B2B-led model across markets and consistent compliance track record. About 67% of our revenue comes from US and 18% from India.”

The company will be commissioning additional capacity to support future portfolio of complex injectables.

The company’s revenue from operations was at Rs. 2,633.24 crore for the year ended March 2020, while net profit stood at Rs. 772.8 crore during this period.

Established in Hyderabad, India in 1978, Gland Pharma is one of the fastest growing small molecule generic injectables-focused company, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets in rest of the world.

Gland Pharma has seven manufacturing facilities in India, comprising four facilities for finished formulations and three facilities. It has established a portfolio of injectables products across various therapeutics segments and delivery systems are present in sterile injectables, oncology and ophthalmics.


* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |